Cardlytics, Inc. (NASDAQ:CDLX) Receives $6.92 Consensus Target Price from Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have earned a consensus rating of “Hold” from the seven research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $6.92.

CDLX has been the subject of several research reports. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, November 7th. Evercore ISI assumed coverage on shares of Cardlytics in a research report on Friday, October 11th. They set an “in-line” rating and a $4.00 target price for the company. Finally, Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 6th.

Insider Activity at Cardlytics

In related news, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the completion of the transaction, the chief executive officer now directly owns 178,519 shares in the company, valued at $687,298.15. The trade was a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alexis Desieno sold 25,118 shares of the company’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $3.43, for a total value of $86,154.74. Following the completion of the transaction, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,691 shares of company stock worth $237,767. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Sanctuary Advisors LLC purchased a new stake in Cardlytics in the third quarter valued at approximately $82,000. Barclays PLC lifted its stake in Cardlytics by 223.9% during the third quarter. Barclays PLC now owns 58,026 shares of the company’s stock worth $186,000 after purchasing an additional 40,112 shares during the last quarter. Geode Capital Management LLC boosted its stake in Cardlytics by 7.5% in the third quarter. Geode Capital Management LLC now owns 1,053,178 shares of the company’s stock worth $3,371,000 after buying an additional 73,484 shares in the last quarter. Quadrature Capital Ltd bought a new position in shares of Cardlytics during the 3rd quarter valued at $63,000. Finally, RBF Capital LLC grew its stake in shares of Cardlytics by 311.9% during the third quarter. RBF Capital LLC now owns 488,128 shares of the company’s stock valued at $1,562,000 after buying an additional 369,620 shares during the last quarter. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Price Performance

Shares of NASDAQ CDLX opened at $3.73 on Wednesday. The company has a market capitalization of $189.56 million, a PE ratio of -0.61 and a beta of 1.53. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 2.40. The stock’s 50 day moving average price is $3.90 and its 200-day moving average price is $5.38. Cardlytics has a twelve month low of $2.89 and a twelve month high of $20.52.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.18. The business had revenue of $67.06 million for the quarter, compared to analysts’ expectations of $57.77 million. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The business’s revenue was down 15.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.26) earnings per share. On average, equities analysts anticipate that Cardlytics will post -1.52 EPS for the current year.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.